On Friday, September 10, 2021, researchers from MAPS Public Benefit Corporation (MAPS PBC) conducted the official site initiation visit for the cross-over extension study for MAPS-sponsored Phase 3 trials of MDMA-assisted therapy for posttraumatic stress disorder (PTSD) at the study site in Madison, Wisconsin. All the subjects who received therapy plus placebo in the double-blind portion of the Phase 3 study have the opportunity to volunteer to go through the study protocol again for free to receive therapy plus MDMA.
On September 17, 2021, the first crossover study participant was treated at the Boulder, Colorado study site. The next participant is scheduled to receive treatment at our Charleston, South Carolina study site in several weeks.
